IP Verse

Tablets Comprising Eltrombopag Olamine

Patent No. EP4218732 (titled "Tablets Comprising Eltrombopag Olamine") was filed by Novartis on Aug 1, 2007. The application was issued on Mar 26, 2025.

Patent Summary

Pharmaceutical tablet formulation for treating thrombocytopenia, comprising eltrombopag olamine, that maintains therapeutic efficacy through controlled dissolution and disintegration properties. The tablet formulation incorporates a wet granulation process using mannitol and microcrystalline cellulose as diluents, with a binder of polyvinylpyrrolidone, lubricant of magnesium stearate, and a disintegrant of sodium starch glycolate. The formulation achieves a defined particle size distribution with a specific particle size range of 10-90 microns, and a film coat containing no coordinating metals or less than 0.025 parts of Compound B.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DEVA HOLDING ANONIM SIRKETIDec 16, 2025-
ELKINGTON AND FIFESep 9, 2025ELKINGTON AND FIFE
STADA ARZNEIMITTELAug 5, 2025MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4218732

NOVARTIS
Application Number
EP23166852A
Filing Date
Aug 1, 2007
Status
Granted And Under Opposition
Feb 21, 2025
Publication Date
Mar 26, 2025
External Links
Slate, Register , Google Patents